NO20020329D0 - Antitumor antistoffer, proteiner og anvendelser derav - Google Patents

Antitumor antistoffer, proteiner og anvendelser derav

Info

Publication number
NO20020329D0
NO20020329D0 NO20020329A NO20020329A NO20020329D0 NO 20020329 D0 NO20020329 D0 NO 20020329D0 NO 20020329 A NO20020329 A NO 20020329A NO 20020329 A NO20020329 A NO 20020329A NO 20020329 D0 NO20020329 D0 NO 20020329D0
Authority
NO
Norway
Prior art keywords
proteins
tumor antibodies
antibodies
expressed
disclosed
Prior art date
Application number
NO20020329A
Other languages
English (en)
Other versions
NO20020329L (no
NO329234B1 (no
Inventor
Kenneth L Rock
Dancella Fernandes
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of NO20020329D0 publication Critical patent/NO20020329D0/no
Publication of NO20020329L publication Critical patent/NO20020329L/no
Publication of NO329234B1 publication Critical patent/NO329234B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20020329A 1999-07-23 2002-01-22 Isolert antistoff eller antigenbindende fragment derav samt anvendelse derav, hybridom cellelinje, farmasoytisk preparat, utstyrssett, tumorcelle-innsiktningsmiddel samt anvendelse derav og fremgangsmate for isolering av et protein NO329234B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14533799P 1999-07-23 1999-07-23
PCT/US2000/019589 WO2001007481A1 (en) 1999-07-23 2000-07-18 Antitumor antibodies, proteins, and uses thereof

Publications (3)

Publication Number Publication Date
NO20020329D0 true NO20020329D0 (no) 2002-01-22
NO20020329L NO20020329L (no) 2002-02-25
NO329234B1 NO329234B1 (no) 2010-09-20

Family

ID=22512634

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020329A NO329234B1 (no) 1999-07-23 2002-01-22 Isolert antistoff eller antigenbindende fragment derav samt anvendelse derav, hybridom cellelinje, farmasoytisk preparat, utstyrssett, tumorcelle-innsiktningsmiddel samt anvendelse derav og fremgangsmate for isolering av et protein

Country Status (21)

Country Link
EP (1) EP1200476B1 (no)
JP (2) JP4842476B2 (no)
KR (1) KR20020034164A (no)
CN (1) CN1390233A (no)
AT (1) ATE432292T1 (no)
AU (1) AU6221200A (no)
BR (1) BR0012704A (no)
CA (1) CA2380066C (no)
CZ (1) CZ303771B6 (no)
DE (1) DE60042273D1 (no)
ES (1) ES2327894T3 (no)
HU (1) HU229416B1 (no)
IL (2) IL147810A0 (no)
MX (1) MXPA02000846A (no)
NO (1) NO329234B1 (no)
NZ (2) NZ530390A (no)
PL (1) PL204822B1 (no)
PT (1) PT1200476E (no)
RU (1) RU2002104713A (no)
WO (1) WO2001007481A1 (no)
ZA (1) ZA200200856B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
JP4842476B2 (ja) * 1999-07-23 2011-12-21 ユニバーシティ オブ マサチューセッツ 抗腫瘍抗体、タンパク質、及びそれらの使用
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
AU2002351374A1 (en) * 2001-12-11 2003-06-23 Corixa Corporation Antibodies to treat cancer
CN1468956A (zh) * 2002-07-15 2004-01-21 杨 琴 高效表达治疗肿瘤的抗体的重组病毒及其用途
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104652A (en) * 1986-11-13 1992-04-14 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against GD3 ganglioside together with IL-2
EP0267615A3 (en) * 1986-11-13 1989-05-03 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
JP4842476B2 (ja) * 1999-07-23 2011-12-21 ユニバーシティ オブ マサチューセッツ 抗腫瘍抗体、タンパク質、及びそれらの使用

Also Published As

Publication number Publication date
NZ530390A (en) 2005-09-30
IL187595A0 (en) 2008-03-20
HUP0202270A3 (en) 2012-09-28
MXPA02000846A (es) 2002-10-23
EP1200476B1 (en) 2009-05-27
IL187595A (en) 2013-05-30
CA2380066A1 (en) 2001-02-01
RU2002104713A (ru) 2003-08-27
WO2001007481A1 (en) 2001-02-01
DE60042273D1 (de) 2009-07-09
WO2001007481A9 (en) 2002-08-29
NO20020329L (no) 2002-02-25
BR0012704A (pt) 2002-07-02
CN1390233A (zh) 2003-01-08
JP2003508525A (ja) 2003-03-04
PL204822B1 (pl) 2010-02-26
CZ303771B6 (cs) 2013-05-02
PL353872A1 (en) 2003-12-01
EP1200476A1 (en) 2002-05-02
JP2011219477A (ja) 2011-11-04
CZ2002288A3 (cs) 2002-06-12
CA2380066C (en) 2011-07-05
JP4842476B2 (ja) 2011-12-21
ES2327894T3 (es) 2009-11-05
HU229416B1 (en) 2013-12-30
ATE432292T1 (de) 2009-06-15
PT1200476E (pt) 2009-08-10
NZ516771A (en) 2004-02-27
IL147810A0 (en) 2002-08-14
NO329234B1 (no) 2010-09-20
KR20020034164A (ko) 2002-05-08
AU6221200A (en) 2001-02-13
EP1200476A4 (en) 2004-11-17
HUP0202270A2 (en) 2002-10-28
ZA200200856B (en) 2003-07-30

Similar Documents

Publication Publication Date Title
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MXPA02004666A (es) Gelatinas recombinantes.
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
TR199701462T1 (xx) DNA Dizisi ve bununla kodlanm�� meme'ye �zel g���s kanseri proteini.
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
YU17603A (sh) Sintetički proteini koji stimulišu eritropoezu
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
ID23374A (id) Halogenopirimidin
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
DE69634077D1 (de) Haemophilus adhäsionsproteinen
DE69229394T2 (de) Zusammensetzungen und methoden zur behandlung von kleinzell und nicht-kleinzell lungenkrebsen
AU580350B2 (en) Process for synthesising peptides
ATE316574T1 (de) Verwendung von ulip proteinen zur diagnose und therapie von krebs und paraneoplastischen neurologischen syndromen
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
IT1262954B (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
ES2094228T3 (es) Peptidos anticoagulantes.
TR200003608T2 (tr) Moraxella Catarrhalis'e ait BASB027 proteinleri ve genleri.
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
ATE231887T1 (de) Protein mit anti-tumorwirkung
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
EP0821691A4 (en) METHOD FOR SYNTHESIS OF GM2

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees